Reed Jobs Raises $200M+ for Cancer Fund – Blending VC & Philanthropy

Driven by a personal commitment to overcoming cancer, Reed Jobs, son of Apple founder Steve Jobs, is significantly expanding his venture capital firm, Yosemite. The firm has secured over $200 million in funding for a second investment round, building on an initial fund launched in 2023.

A New Approach to Cancer Funding

Yosemite distinguishes itself from traditional venture capital firms by combining philanthropic grants with direct investment in early-stage companies. This dual approach allows for support of high-risk research without immediate commercialization pressures, while simultaneously providing capital to promising startups. According to an interview with Forbes, Jobs aims to transform cancer from a fatal disease into a manageable, chronic condition.

Did You Know? Reed Jobs’ firm, Yosemite, is named after the national park where his parents were married.

From Stanford Research to Yosemite’s Founding

Jobs’ dedication to cancer research began early, with a Stanford University cancer research internship at age 15. While initially considering a medical career, he shifted his focus to history and eventually joined the Emerson Collective, his mother Laurene Powell Jobs’ family foundation. There, he served as Health Director, concentrating on cancer research strategy. This experience laid the groundwork for the creation of Yosemite in 2023.

Investing in Innovation

The $200 million funding round includes investment from major players like Amgen, the Memorial Sloan Kettering Cancer centre, investor John Doerr and Laurene Powell Jobs. Yosemite plans approximately 25 investments in early-stage companies. The firm’s portfolio already includes Chai Discovery, Tune Therapeutics, and Azalea Therapeutics, each pursuing innovative cancer treatment approaches.

Expert Insight: Yosemite’s blended funding model—combining philanthropic grants with venture capital—represents a potentially significant shift in how early-stage cancer research is financed, addressing the critical “valley of death” between initial discovery and commercial viability.

Chai Discovery, founded in San Francisco in 2024, utilizes artificial intelligence to develop proteins targeting difficult-to-treat cancers. Tune Therapeutics is focused on new therapies for liver cancer caused by Hepatitis B. Azalea Therapeutics, a spin-off from UC Berkeley, is pioneering gene therapies that modify genes directly within the body.

Frequently Asked Questions

What is Yosemite’s primary focus?

Yosemite is a venture capital firm focused on investing in and funding research related to cancer treatment.

How does Yosemite differ from traditional VC firms?

Yosemite combines philanthropic grants for high-risk research with traditional venture capital investments in early-stage companies.

Who is involved in funding Yosemite’s second fund?

Investors include Amgen, Memorial Sloan Kettering Cancer centre, John Doerr, and Laurene Powell Jobs.

As Yosemite continues to invest in promising cancer research, will this innovative funding model inspire others to bridge the gap between scientific discovery and patient care?